Document:

EX-10.17

 Exhibit 10.17 
  

 
 May 4, 2015 
 Henry
Hebel 
 [address] 
 Re:   Offer of Employment - Vice
President of Operations. 
 Dear Henry, 
 On behalf of Aeglea
Development Company, Inc. (the “Company”), it is my pleasure to formally offer you the position of Vice President of Operations, with an anticipated start date of May 26, 2015. This letter contains an overview of the responsibilities,
compensation and benefits associated with this position. We are hopeful that you will accept this offer and look forward to the prospect of having a mutually successful relationship with you. 

EMPLOYMENT 
 During employment with the Company, you will
be expected to devote your full business time and attention to the business and affairs of the Company. You will report to David Lowe, President & CEO and will be expected to abide by all of the Company’s employment policies and
procedures, including but not limited to the Company’s policies prohibiting employment discrimination and harassment and the Company’s rules regarding proprietary information and trade secrets. The Company acknowledges that you are also a
member and part-time employee of The Hebel Consulting Group LLC and agrees that, in such capacity, you will be able to engage in consulting activities, subject to the Company’s prior written consent with respect to each such engagement (at
Company’s discretion), and provided that such consulting activities will not interfere or conflict with your responsibilities as a full time employee of the Company, will occur on your own time and will not limit your obligations to the
Company, as set forth in this letter and the EMPLOYEE INVENTION ASSIGNMENT, CONFIDENTIALITY AND NON-COMPETITION AGREEMENT to be entered into between you and the Company. All such consulting activities as of the start date of your employment are
described in Exhibit B attached hereto. Upon, Company’s consent to any additional such consulting engagement, the parties will update Exhibit B. 

BASE SALARY 
 While employed by the Company, your annual
base salary will be $240,000 less any federal, state and local payroll taxes and other withholdings legally required or properly requested by you (the “Base Salary”). The Base Salary will be payable to you in accordance with the
Company’s regular payroll practices and procedures and will be subject to periodic review and adjustment, at the Company’s discretion. 

 BONUS 
 For
each calendar year of employment (beginning with 2015), you will be eligible to receive a discretionary bonus in an amount targeted at twenty-five percent (25%) of the Base Salary paid to you in that calendar year (the “Annual
Bonus”). Your entitlement to receive an Annual Bonus and the amount thereof will be determined by the Board in its sole discretion based on (i) the Company’s financial performance and financial resources as well as (ii) the
Board’s evaluation of your performance for a given year and your achievement of certain objectives in the applicable calendar year as set forth and approved by the Board. You will be eligible for an Annual Bonus for a given calendar year only
if you remain employed by the Company through the date that such Annual Bonus is paid; as a result, you are not entitled to any Annual Bonus for which you might otherwise be eligible if your employment ends for any reason before the date of payment.
Nothing guarantees your receipt of an Annual Bonus in any amount if the specified objectives are not met and/or any of the other conditions set forth herein are not satisfied in a given calendar year. 

STOCK 
 As additional compensation, and subject to
approval by the Board of Directors of Aeglea BioTherapeutics, Inc. (“Parent”), the Company will arrange for the grant to you by Parent of: 
  

	 	i)	an option to purchase 351,142 shares of Parent’s common stock (the “First Option”). One-fourth of the total number of shares subject to the First Option will vest upon your completion of 12 months of
employment, and one sixteenth (1/16’h) of the total number of shares subject to the First Option will vest each quarter over the following twelve (12) quarters thereafter. 

 

	 	ii)	an option to purchase 129,874 shares of Parent’s common stock (the “Second Option”). One-fourth of the total numher of shares subject to the Second Option will vest upon your completion of 24 months of
employment, and one sixteenth (1/16’h) of the total number of shares subject to the Second Option will vest each quarter over the following twelve (12) quarters thereafter. 

Each of the First Option and the Second Option will be granted pursuant to and subject to the terms and conditions of Parent’s equity incentive plan and
will be further subject to the terms of an option agreement as approved by Parent’s Board of Directors setting forth the vesting conditions and other restrictions. To the extent there is any discrepancy between this Offer Letter and the terms
of any option agreement, the option agreement will control. 
 BENEFITS 

During employment with the Company, you will be eligible to participate in any medical, dental, profit sharing or other employee benefit plans of the Company,
if any, on the same basis and subject to the same qualifications and limitations, as other similarly situated employees in the Company. Please note that all Company benefit plans will be governed by and subject to plan documents and/or written
policies. You will also be eligible to receive any paid holiday time and vacation time observed by the Company in accordance with the Company’s policies and procedures. The Company reserves the right to amend, modify, and/or terminate any of
its employee benefit plans or policies, or any other terms of your employment at any time. 

  
 2 

 EXPENSE REIMBURSEMENT 

The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the
Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses. 

EMPLOYMENT AT WILL 
 Although we hope for a long and
mutually beneficial relationship, this letter is not a contract of employment for a definite term. Employment with the Company is “at will,” and is not guaranteed for any specific length of service or any specific position. Accordingly, as
an “at-will” employee, the Company may terminate your employment or you may resign your employment with the Company at any time, for any reason or no reason. 

COVENANTS 
 This offer letter and your employment is
subject to a successful criminal background check and documentation of authorization to work in the United States. No later than your first day of employment you will be expected to sign a Proprietary Information and Inventions Assignment Agreement
(the “Agreement”) in the form attached hereto as Exhibit A. Your employment with the Company is contingent upon your execution of this Agreement. 

EMPLOYEE REPRESENTATIONS 
 Please understand it is the
policy of the Company not to solicit or accept proprietary information and / or trade secrets of other companies or third parties. lf you have or have had access to trade secrets or other confidential proprietary information from your former
employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software,
customer lists, and business plans or strategies. 
 In making this employment offer, the Company has relied on your representation that: (a) you are
not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any non-competition or non-solicitation
agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all of your
obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not
generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same. 

This offer, once accepted, and together with the confidentiality agreement referred to above, constitutes the entire agreement between you and the Company
with respect to the subject matter hereof and supersedes all prior offers, negotiations and agreements, if any, whether written or oral, relating to such subject matter. You acknowledge that neither the Company nor its agents have made any promise,
representation or warranty whatsoever, either express or implied, written or oral, which is not contained in this agreement for the purpose of inducing you to execute the agreement, and you acknowledge that you have executed this agreement in
reliance only upon such promises, representations and warranties as are contained herein. 

  
 3 

 We look forward to your contribution to the Company. If you have any questions about the terms of this offer or
the contents of this letter, please feel free to contact me. In acknowledgment and acceptance of our offer, please sign this Offer Letter as well as the Agreement and return both documents to me directly. 

Sincerely, 
  

			
	AEGLEA DEVELOPMENT COMPANY, INC.
		
	By:	 	  /s/ David Lowe

		 	David Lowe, President & CEO

					
	
	AGREED AND ACCEPTED:
		
	 /s/ Henry L. Hebel	 	May 4, 2015
	Signature	 	Date

  
 4 

 EXHIBIT A 

Non-disclosure Agreement and Invention Rights Assignment are attached. 

  
 5 

 EMPLOYEE INVENTION ASSIGNMENT, CONFIDENTIALITY AND NON-COMPETITION AGREEMENT 

In consideration of, and as a condition of my employment with Aeglea Development Company, Inc., a Delaware corporation (the
“Company”), I, as the “Employee” signing this Employee Invention Assignment, Confidentiality and Non-Competition Agreement (this
“Agreement”), hereby represent to the Company, and the Company and I hereby agree as follows: 
 1.
Purpose of Agreement. I understand that the Company is engaged in a continuous program of research, development, production and/or marketing in connection with its current and projected business and that it is critical for the Company to
preserve and protect its proprietary information, its rights in certain inventions and works and in related intellectual property rights. Accordingly, I am entering into this Agreement, whether or not I am expected to create inventions or other
works of value for the Company. As used in this Agreement, “Inventions” means proprietary information, trade secrets, know-how, data, original works of authorship, inventions, improvements, discoveries, designs, technology,
computer software programs, databases, mask works, formulas, processes, methods, techniques, protocols, assays and compositions of matter. 

2. Disclosure of Inventions. I will promptly disclose in confidence to the Company, or to any person designated by it, all
Inventions that I make, create, conceive or first reduce to practice, either alone or jointly with others, during the period of my employment, whether or not in the course of my employment, and whether or not patentable, copyrightable or protectable
as trade secrets. As the sole exception to the foregoing and without limiting my other obligations under this Agreement, the foregoing shall not apply to Inventions that I make, create, conceive or first reduce to practice, either alone or jointly
with others, in the course of consulting activities conducted by me in my capacity as a member and part-time employee of The Hebel Consulting Group LLC and listed in Exhibit B to the offer letter dated May 4, 2015 between me and the Company (as
may be updated from time to time in accordance with such offer letter). 
 3. Work for Hire; Assigned Inventions. I
acknowledge and agree that any copyrightable works prepared by me within the scope of my employment will be “works made for hire” under the Copyright Act and that the Company will be considered the author and owner of such copyrightable
works. I agree that all Inventions that I make, create, conceive or first reduce to practice during the period of my employment, whether or not in the course of my employment, and whether or not patentable, copyrightable or protectable as trade
secrets, and that (i) are developed using equipment, supplies, facilities or trade secrets of the Company; (ii) result from work performed by me for the Company; or (iii) relate to the Company’s business or actual or demonstrably
anticipated research or development (the “Assigned Inventions”), will be the sole and exclusive property of the Company. 

4. Excluded Inventions and Other Inventions. Attached hereto as Exhibit A is a list describing all existing
Inventions, if any, that may relate to the Company’s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the Effective Date (as defined in Section 25, below), and which
are not to be assigned to the Company (“Excluded Inventions”). If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions

 
that may relate to the Company’s business or actual or demonstrably anticipated research or development. For purposes of this Agreement, “Other Inventions” means
Inventions in which I have or may have an interest, as of the Effective Date or thereafter, other than Assigned Inventions and Excluded Inventions. I acknowledge and agree that if, in the scope of my employment, I use any Excluded Inventions or any
Other Inventions, or if I include any Excluded Inventions or Other Inventions in any product or service of the Company or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the
exercise by the Company of any rights assigned to the Company under this Agreement, I will immediately so notify the Company in writing. Unless the Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I
hereby grant to the Company, in such circumstances (whether or not I give the Company notice as required above), a perpetual, irrevocable, nonexclusive, transferable, world-wide, royalty-free license to use, disclose, make, sell, offer for sale,
import, copy, distribute, modify and create works based on, perform, and display such Excluded Inventions and Other Inventions, and to sublicense third parties in one or more tiers of sublicensees with the same rights. 

5. Exception to Assignment. I understand that the Assigned Inventions will not include, and the provisions of this Agreement
requiring assignment of inventions to the Company do not apply to an invention for which no equipment, supplies, facility or trade secret information of the Company was used and which was developed entirely on my own time, except for those
inventions that either: (1) relate at the time of conception or reduction to practice of the invention to the Company’s business or to actual or demonstrably anticipated research or development of the Company; or (2) result from any
work performed by me for the Company. 
 6. Assignment of Rights. I agree to assign, and do hereby irrevocably transfer and
assign, to the Company: (i) all of my rights, title and interests in and with respect to any Assigned Inventions; (ii) all patents, patent applications, copyrights, mask works, rights in databases, trade secrets, and other intellectual
property rights, worldwide, in any Assigned Inventions, along with any registrations of or applications to register such rights; and (iii) to the extent assignable, any and all Moral Rights (as defined below) that I may have in or with respect
to any Assigned Inventions. I also hereby forever waive and agree never to assert any Moral Rights I may have in or with respect to any Assigned Inventions and any Excluded Inventions or Other Inventions licensed to the Company under Section 4,
even after termination of my employment with the Company. “Moral Rights” means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, to withdraw from circulation or
control the publication or distribution of a work, and any similar right, regardless of whether or not such right is denominated or generally referred to as a “moral right.” 

7. Assistance. I will assist the Company in every proper way to obtain and enforce for the Company all patents, copyrights, mask
work rights, trade secret rights and other legal protections for the Assigned Inventions, worldwide. I will execute and deliver any documents that the Company may reasonably request from me in connection with providing such assistance. My
obligations under this section will continue beyond the termination of my employment with the Company; provided that the Company agrees to compensate me at a reasonable rate after such termination for time and expenses actually spent by me at
the Company’s request in providing such assistance. I hereby appoint the Secretary of the Company as my attorney-in-fact to execute documents on my behalf for this purpose. I agree that this appointment is coupled with an interest and will not
be revocable. 

  
 2 

 8. Proprietary Information. I understand that my employment by the Company creates
a relationship of confidence and trust with respect to any information or materials of a confidential or secret nature that may be made, created or discovered by me or that may be disclosed to me by the Company or a third party in relation to the
business of the Company or to the business of any parent, subsidiary, affiliate, customer or supplier of the Company, or any other party with whom the Company agrees to hold such information or materials in confidence (the “Proprietary
Information”). Without limitation as to the forms that Proprietary Information may take, I acknowledge that Proprietary Information may be contained in tangible material such as writings, drawings, samples, electronic media, or computer
programs, or may be in the nature of unwritten knowledge or know-how. Proprietary Information includes, but is not limited to, Assigned Inventions, proprietary information, trade secrets, know-how, data (including technical, scientific and clinical
data), original works of authorship, records, laboratory notebooks, inventions, improvements, discoveries, designs, technology, computer software programs, databases, mask works, formulas, processes, methods, techniques, protocols, assays,
compositions of matter, specimens, compounds, samples, materials, marketing plans, product plans, products, product candidates, regulatory, marketing, financial or other business information, personnel information, contract information, customer and
supplier lists, and research and development, including research relating to, but not limited to, in vitro systems, DNA and amino acid sequences, cell strains, biological or chemical substances and compounds. 

9. Confidentiality. At all times, both during my employment and after its termination, I will keep and hold all Proprietary
Information in strict confidence and trust. I will not use or disclose any Proprietary Information without the prior written consent of the Company in each instance, except as may be necessary to perform my duties as an employee of the Company for
the benefit of the Company. Upon termination of my employment with the Company, I will promptly deliver to the Company all documents and materials of any nature pertaining to my work with the Company, and I will not take with me or retain in any
form any documents or materials or copies containing any Proprietary Information. 
 10. Physical Property. All documents,
supplies, equipment and other physical property furnished to me by the Company or produced by me or others in connection with my employment will be and remain the sole property of the Company. I will return to the Company all such items when
requested by the Company, excepting only my personal copies of records relating to my employment or compensation and any personal property I bring with me to the Company and designate as such. Even if the Company does not so request, I will upon
termination of my employment return to the Company all Company property, and I will not take with me or retain any such items. 
 11.
No Breach of Prior Agreements. I represent that my performance of all the terms of this Agreement and my duties as an employee of the Company will not breach any invention assignment, proprietary information, confidentiality,
non-competition, or other agreement with any former employer or other party. I represent that I will not bring with me to the Company or use in the performance of my duties for the Company any documents or materials or intangibles of my own or of a
former employer or third party that are not generally available for use by the public or have not been legally transferred to the Company. 

  
 3 

 12. “At Will” Employment. I understand that this Agreement does not
constitute a contract of employment or obligate the Company to employ me for any stated period of time. I understand that I am an “at will” employee of the Company and that my employment can be terminated at any time, with or without
notice and with or without cause, for any reason or for no reason, by either the Company or by me. I acknowledge that any statements or representations to the contrary are ineffective, unless put into a writing signed by the Company. I further
acknowledge that my participation in any stock option or benefit program is not to be construed as any assurance of continuing employment for any particular period of time. 

13. Company Opportunities; No Conflicting Activities. During the period of my employment, I will at all times devote my best
efforts to the interests of the Company, and I will not, without the prior written consent of the Company, engage in, or encourage or assist others to engage in, any other employment or activity that: (i) would divert from the Company any
business opportunity in which the Company can reasonably be expected to have an interest; (ii) would directly compete with, or involve preparation to compete with, the current or future business of the Company; or (iii) would otherwise
conflict with the Company’s interests or could cause a disruption of its operations or prospects. 
 14. Non-Competition;
Non-Solicitation. 
 (a) Non-Competition. I understand that the Company’s interests in protecting its
investments, goodwill, and technologies make it reasonable for the Company to ask me to agree that I will not compete with the Company for a reasonable period after the termination of my employment for any reason, whether voluntary or involuntary. I
further understand that I will be provided with Proprietary Information during the scope of my employment with the Company. Accordingly, and understanding that the Company’s business is potentially global in scope, I further agree that I will
not, during the twelve month period following the termination of my employment (the “Post-Employment Period”), directly or indirectly, work for or provide service of any kind, as an employee, consultant, director, owner or in
any other capacity, to any person or entity (including any business in planning or formation) that is or intends to be competitive with, or is engaged in the design, development, manufacture, production, marketing, sale or servicing of any product
or the provision of any service that relates in any way to the business then being conducted or planned by the Company and any of its subsidiary or affiliated entities. It will not be deemed to be a violation of this Section 14(a) for me to
make or hold either of the following investments: (a) ownership, as a passive investor, of up to two percent (2%) of any publicly traded company; or (b) an equity interest of up to two percent (2%) in any venture capital fund or
other investment vehicle that makes investments in early stage companies so long as I do not participate in or influence the investment decision process of such fund or vehicle. 

(b) Non-Solicitation of Employees/Consultants. During my employment with the Company and the Post-Employment Period, I will not
directly or indirectly solicit away employees or consultants of the Company for my own benefit or for the benefit of any other person or entity, nor will I encourage or assist others to do so. I acknowledge and agree that even after the expiration
of the 

  
 4 

 
Post-Employment Period, I will not solicit (or encourage or assist others to solicit) away any employees or consultants of the Company if, in so doing, I use or disclose any trade secrets or
other Proprietary Information of the Company. 
 (c) Non-Solicitation of Suppliers/Customers. During my employment with the
Company and the Post-Employment Period, I will not directly or indirectly solicit or otherwise take away customers or suppliers of the Company or otherwise divert or attempt to divert business away from the Company, nor will I encourage or assist
others to do so. I acknowledge and agree that even after the expiration of the Post-Employment Period, I will not solicit (or encourage or assist others to solicit) any customers or suppliers of the Company if, in so doing, I use or disclose any
trade secrets or other Proprietary Information of the Company. 
 (d) Reasonableness. I acknowledge that the post-employment
restrictions on competition and solicitation in this Section 14 are reasonable and necessary in light of the Company’s need to protect its trade secrets and other Proprietary Information and the goodwill of the Company’s business.

 15. Use of Name & Likeness. I hereby authorize the Company to use, reuse, and to grant others the right to use and
reuse, my name, photograph, likeness (including caricature), voice, and biographical information, and any reproduction or simulation thereof, in any form of media or technology now known or hereafter developed, both during and after my employment,
for any purposes related to the Company’s business, such as marketing, advertising, credits, and presentations. 
 16.
Notification. I hereby authorize the Company, during and after the termination of my employment with the Company, to notify third parties, including, but not limited to, actual or potential customers or employers, of the terms of this
Agreement and my responsibilities hereunder. 
 17. Injunctive Relief. I understand that a breach or threatened breach of this
Agreement by me may cause the Company to suffer irreparable harm and that the Company will therefore be entitled to injunctive relief to enforce this Agreement. 

18. Governing Law; Severability. This Agreement is intended to supplement, and not to supersede, any rights the Company may have
in law or equity with respect to the duties of its employees and the protection of its trade secrets. This Agreement will be governed by and construed in accordance with the laws of the State of Texas without giving effect to any principles of
conflict of laws that would lead to the application of the laws of another jurisdiction. If any provision of this Agreement is invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible, given
the fundamental intentions of the parties when entering into this Agreement. To the extent such provision cannot be so enforced, it will be stricken from this Agreement and the remainder of this Agreement will be enforced as if such invalid, illegal
or unenforceable provision had never been contained in this Agreement. 

  
 5 

 19. Counterparts. This Agreement may be executed in any number of counterparts,
each of which when so executed and delivered will be deemed an original, and all of which together will constitute one and the same agreement. 

20. Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement and understanding of
the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between the parties hereto with respect to such subject matter. 

21. Amendment and Waiver. This Agreement may be amended only by a written agreement executed by each of the parties to this
Agreement. No amendment or waiver of, or modification of any obligation under, this Agreement will be enforceable unless specifically set forth in a writing signed by the party against which enforcement is sought. A waiver by either party of any of
the terms and conditions of this Agreement in any instance will not be deemed or construed to be a waiver of such term or condition with respect to any other instance, whether prior, concurrent or subsequent. 

22. Successors and Assigns; Assignment. Except as otherwise provided in this Agreement, this Agreement, and the rights and
obligations of the parties hereunder, will bind and benefit the parties and their respective successors, assigns, heirs, executors, administrators, and legal representatives. The Company may assign any of its rights and obligations under this
Agreement. I understand that I will not be entitled to assign or delegate this Agreement or any of my rights or obligations hereunder, whether voluntarily or by operation of law, except with the prior written consent of the Company. 

23. Further Assurances. The parties will execute such further documents and instruments and take such further actions as may be
reasonably necessary to carry out the purposes and intent of this Agreement. Upon termination of my employment with the Company, I will execute and deliver a document or documents in a form reasonably requested by the Company confirming my agreement
to comply with the post-employment obligations contained in this Agreement. 
 24. Acknowledgement. I certify and acknowledge
that I have carefully read all of the provisions of this Agreement and that I understand and will fully and faithfully comply with this Agreement. 

[Section 25 and signatures follow on the next page.] 

  
 6 

 25. Effective Date of Agreement. This Agreement is and will be effective on
and after the first day of my employment by the Company (the “Effective Date”). 
  

							
	Company: Aeglea Development Company, Inc.	 		 	Employee:
				
	By:	 	/s/ David G Lowe	 		 	/s/ Henry Hebel
		 		 		 	Signature
				
	Name:    	 	David G Lowe	 		 	Henry Hebel
		 		 		 	Name
				
	Title:	 	President & CEO	 		 	

 Exhibit A 

LIST OF EXCLUDED INVENTIONS UNDER SECTION 4 
  

					
	 Title
	 	 Date
	 	 Identifying Number

or Brief Description

		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	

 X         No inventions, improvements, or original works of authorship 

            Additional sheets attached 

Signature of Employee: /s/ Henry
Hebel                         

Print Name of Employee: Henry
Hebel                           

Date:
  5/5/15                                      
               

 EXHIBIT B 

(Dated May 4, 2015) 
  
 

 
 Exhibit B to Henry Hebel Offer Letter dated May 4, 2015 

Amended and agreed as of Jan 13, 2016 
 Consulting activities:

 Terapio Inc. – Austin, TX – radiation countermeasure product development and business 

Twister Biotech – Houston, TX – minivector technology business and product developmentEX-10.18

 Exhibit 10.18 

VICE PRESIDENT SEVERANCE AGREEMENT 

This Vice President Severance Agreement (the “Agreement”) is entered into as of January 14, 2016 (the “Effective
Date”) by and between Henry L. Hebel (the “Employee”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”). 

1. Term of Agreement. 
 Except to the
extent renewed as set forth in this Section 1, this Agreement shall terminate the earlier of the third (3rd) anniversary of the Effective Date (the “Expiration Date”) or
the date the Employee’s employment with the Company or its subsidiary, as applicable, terminates for a reason other than a Qualifying Termination or CIC Qualifying Termination; provided however, if a definitive agreement relating to a
Change in Control has been signed by the Company on or before the Expiration Date, then this Agreement shall remain in effect through the earlier of: 

(a) The date the Employee’s employment with the Company or its subsidiary, as applicable, terminates for a reason other than a Qualifying
Termination or CIC Qualifying Termination, or 
 (b) The date the Company or its subsidiary, as applicable, has met all of its obligations
under this Agreement following a termination of the Employee’s employment with the Company or its subsidiary, as applicable, due to a Qualifying Termination or CIC Qualifying Termination. 

This Agreement shall renew automatically and continue in effect for three (3) year periods measured from the initial Expiration Date,
unless the Company or its subsidiary provides Employee notice of non-renewal at least three (3) months prior to the date on which this Agreement would otherwise renew. For the avoidance of doubt, and notwithstanding anything to the contrary in
Section 2 or 3 below, the Company’s non-renewal of this Agreement shall not constitute a Qualifying Termination or CIC Qualifying Termination. 

2. Qualifying Termination. If the Employee is subject to a Qualifying Termination, then, subject to Sections 4, 9, and 10 below, Employee will be
entitled to the following benefits: 
 (a) Severance Benefits. The Company or its subsidiaries shall pay Employee a severance amount
equivalent to twelve (12) weeks of base salary (at the rate in effect immediately prior to the actions that resulted in the Qualifying Termination) plus an additional 2 weeks of base salary for each full year of employment with the Company or
its subsidiaries, up to a maximum benefit of six (6) months of base salary (the “Severance”). The Severance shall be paid through salary continuation in equal installments in accordance with the Company’s or its
subsidiary’s, as applicable, standard payroll procedures, with the initial payment to occur on the first payroll date following the sixtieth (60th) day following Employee’s
Separation, with the first installment to include a catchup payment for amounts covering the period from the date of Separation through the first payment date, provided that the Release Conditions have been satisfied. However, if the period
comprising the sum of the sixty (60)-day period described in the preceding sentence and the ten (10)-day period described in Section 7(e)(3) below spans two calendar years, then the payments which constitute deferred compensation subject to
Section 409A will not in any case commence in the first calendar year. The period between the date of Executive’s Separation and final Severance payment shall be referred to herein as the “Severance Period.” 

(b) Continued Employee Benefits. If Executive timely elects continued coverage under the Consolidated Omnibus Budget Reconciliation Act
(“COBRA”), the Company or its subsidiaries shall pay the full amount of Executive’s COBRA premiums on behalf of the Executive for the Executive’s continued coverage under the Company’s or its subsidiary’s, as
applicable, health, dental and vision plans, including coverage for the Executive’s eligible dependents, for the Severance Period. Notwithstanding the foregoing, if the Company, in its sole discretion, determines that it cannot provide the
foregoing subsidy of COBRA coverage 

 
without potentially violating or causing the Company or its subsidiary to incur additional expense as a result of noncompliance with applicable law (including, without limitation,
Section 2716 of the Public Health Service Act), the Company or its subsidiary instead shall provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue the
group health coverage in effect on the date of the Separation (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage and
shall commence on the later of (i) the first day of the month following the month in which Executive experiences a Separation and (ii) the effective date of the Company’s determination of violation of applicable law, and shall end on
the earlier of (x) the effective date on which Executive becomes covered by a health, dental or vision insurance plan of a subsequent employer, and (y) the last day of the Severance Period, provided that, any taxable payments under
this Section 2(b) will not be paid before the first business day occurring after the sixtieth (60th) day following the Separation and, once they commence, will include any unpaid amounts
accrued from the date of Executive’s Separation (to the extent not otherwise satisfied with continuation coverage). However, if the period comprising the sum of the sixty (60)-day period described in the preceding sentence and the ten (10)-day
period described in Section 7(e)(3) below spans two calendar years, then the payments which constitute deferred compensation subject to Section 409A will not in any case be paid in the first calendar year. Executive shall have no right to
an additional gross-up payment to account for the fact that such COBRA premium amounts are paid on an after-tax basis. 
 3. CIC Qualifying
Termination. If the Employee is subject to a CIC Qualifying Termination, then, subject to Sections 4, 9, and 10 below, Employee will be entitled to the following benefits: 

(a) Severance Benefits. The Company or its subsidiary shall pay the Employee six (6) months of his or her monthly base salary (at
the rate in effect immediately prior to the actions that resulted in the Separation, such amount, the “CIC Severance”). The CIC Severance shall be paid through salary continuation in equal installments in accordance with the
Company’s or its subsidiary’s, as applicable, standard payroll procedures, with the initial payment to occur on the first payroll date following the sixtieth (60th) day following
Employee’s date of Separation, with the first installment to include a catchup payment for amounts covering the period from the date of Separation through the first payment date, provided that the Release Conditions have been satisfied.
However, if the period comprising the sum of the sixty (60)-day period described in the preceding sentence and the ten (10)-day period described in Section 7(e)(3) below spans two calendar years, then the payments which constitute deferred
compensation subject to Section 409A will not in any case commence in the first calendar year. The period between the date of Executive’s Separation and final CIC Severance payment shall be referred to herein as the “CIC Severance
Period.” 
 (b) Equity. Each of Employee’s then outstanding Equity Awards, including awards that would otherwise vest
only upon satisfaction of performance criteria, shall accelerate and become vested and exercisable as to 100% of the total shares underlying the Equity Award. For awards that would otherwise vest only upon satisfaction of performance criteria, the
foregoing acceleration shall be based on achievement of performance criteria at target, except to the extent otherwise provided in the award agreement evidencing such award. “Equity Awards” means all options to purchase shares of
Company common stock as well as any and all other stock-based awards granted to the Employee, including but not limited to stock bonus awards, restricted stock, restricted stock units or stock appreciation rights. Subject to Section 4, the
accelerated vesting described above shall be effective as of the Separation. 
 (c) Pay in Lieu of Continued Employee Benefits. If
Executive timely elects continued coverage under COBRA, the Company or its subsidiary shall pay the full amount of Executive’s COBRA premiums on behalf of the Executive for the Executive’s continued coverage under the Company’s or its
subsidiary’s, as applicable, health, dental and vision plans, including coverage for the Executive’s eligible dependents, for the CIC Severance Period. Notwithstanding the foregoing, if the Company, in its sole discretion, determines that
it cannot provide the foregoing subsidy of COBRA coverage without potentially violating or causing the Company or its subsidiary to incur additional expense as a result of noncompliance with applicable law (including, without limitation,
Section 2716 of the Public Health Service Act), the Company or its subsidiary instead shall provide to Executive a taxable monthly 

  
 2 

 
payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue the group health coverage in effect on the date of the Separation (which amount shall
be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage, shall commence on the later of (i) the first day of the month following the month
in which Executive experiences a Separation and (ii) the effective date of the Company’s determination of violation of applicable law, and shall end on the earlier of (x) the effective date on which Executive becomes covered by a
health, dental or vision insurance plan of a subsequent employer, and (y) the last day of the CIC Severance Period, provided that, any taxable payments under this Section 3(c) will not be paid before the first business day occurring
after the sixtieth (60th) day following the Separation and, once they commence, will include any unpaid amounts accrued from the date of Executive’s Separation (to the extent not
otherwise satisfied with continuation coverage). However, if the period comprising the sum of the sixty (60)-day period described in the preceding sentence and the ten (10)-day period described in Section 7(e)(3) below spans two calendar years,
then the payments which constitute deferred compensation subject to Section 409A will not in any case be paid in the first calendar year. Executive shall have no right to an additional gross-up payment to account for the fact that such COBRA
premium amounts are paid on an after-tax basis. 
 4. General Release. Any other provision of this Agreement notwithstanding, the benefits under
Section 2 and 3 shall not apply unless the Employee (i) has executed a general release (in a form prescribed by the Company) of all known and unknown claims that he or she may then have against the Company or persons or entities affiliated
with the Company and such release has become effective and (ii) has agreed not to prosecute any legal action or other proceeding based upon any of such claims. The release must be in the form prescribed by the Company, without alterations (this
document effecting the foregoing, the “Release”). The Company or its subsidiary will deliver the form of Release to the Employee within thirty (30) days after the Employee’s Separation. The Employee must execute and return
the Release within the time period specified in the form. 
 5. Accrued Compensation and Benefits. Notwithstanding anything to the contrary in
Section 2 and 3 above, in connection with any termination of employment upon or following a Change in Control (whether or not a Qualifying Termination or CIC Qualifying Termination), the Company or its subsidiary shall pay Employee’s
earned but unpaid base salary and other vested but unpaid cash entitlements for the period through and including the termination of employment, including unused earned vacation pay and unreimbursed documented business expenses incurred by Employee
prior to the date of termination (collectively “Accrued Compensation and Expenses”), as required by law and the applicable Company or its subsidiary, as applicable, plan or policy. In addition, Employee shall be entitled to any
other vested benefits earned by Employee for the period through and including the termination date of Employee’s employment under any other employee benefit plans and arrangements maintained by the Company or its subsidiary, as applicable, in
accordance with the terms of such plans and arrangements, except as modified herein (collectively “Accrued Benefits”). Any Accrued Compensation and Expenses to which the Employee is entitled shall be paid to the Employee in cash as
soon as administratively practicable after the termination, and, in any event, no later than two and one-half (2-1/2) months after the end of the taxable year of the Employee in which the termination occurs or at such earlier time as may be required
by applicable law or Section 10 below, and to such lesser extent as may be mandated by Section 9 below. Any Accrued Benefits to which the Employee is entitled shall be paid to the Employee as provided in the relevant plans and
arrangements. 
 6. Covenants. 
 (a)
Non-Competition. The Employee agrees that the benefits provided in this Agreement are granted in consideration for the ongoing promises and obligations of Employee under his employment agreement and any amendments thereto, including but not
limited to Employee’s obligations concerning non-competition and non-solicitation. 
 (b) Cooperation and Non-Disparagement. The
Employee agrees that, during the Severance Period or the CIC Severance Period, as applicable, he or she shall cooperate with the Company or its subsidiary in every reasonable respect and shall use his or her best efforts to assist the Company or its
subsidiary with the transition of Employee’s duties to his or her successor. The Employee 

  
 3 

 
further agrees that following the date of Separation, he or she shall not in any way or by any means disparage the Company, its subsidiaries, or the members of their Board of Directors or their
officers and employees. 
 7. Definitions. 

(a) “Cause” means (i) an unauthorized use or disclosure by Employee of the Company’s or its
subsidiaries’confidential information or trade secrets, which use or disclosure causes or is reasonably likely to cause material harm to the Company or its subsidiaries, (ii) a material breach of any agreement between Employee and the
Company or its subsidiaries, (iii) a material failure to comply with the Company’s or its subsidiaries’ written policies or rules that has caused or is reasonably likely to cause material injury to the Company, its successor, or its
affiliates, or any of their business, (iv) conviction of, or plea of “guilty” or “no contest” to, a felony under the laws of the United States or any state thereof, (v) willful misconduct that has caused or is
reasonably likely to cause material injury to the Company, its successor, or its affiliates, or any of their business, (vi) embezzlement, (vii) failure to cooperate with the Company or its subsidiaries in any investigation or formal
proceeding if the Company or its subsidiaries has requested Employee’s reasonable cooperation, (viii) violation of any applicable federal, state or foreign statutes or laws that govern or regulate employment, pharmaceutical drugs or
securities, including but not limited to the laws enforced by the federal Equal Employment Opportunity Commission, Department of Labor, Food and Drug Administration, Securities and Exchange Commission and Department of Justice or (ix) a
continued failure to perform assigned duties after receiving written notification of such failure from the Company’s, or its subsidiaries’, as applicable, Chief Executive Officer; provided that Employee must be provided with written
notice of Employee’s termination for “Cause” and Employee must be provided with a thirty (30) day period following Employee’s receipt of such notice to cure the event(s) that trigger “Cause,” with the
Company’s or its subsidiaries’, as applicable, Chief Executive Officer making the final determination whether Employee has cured any Cause. 

(b) “Code” means the Internal Revenue Code of 1986, as amended. 

(c) “Change in Control.” For all purposes under this Agreement, a Change in Control shall mean a “Corporate
Transaction,” as such term is defined in the Company’s 2015 Equity Incentive Plan, as may be amended from time to time, provided that the transaction (including any series of transactions) also qualifies as a change in control under
U.S. Treasury Regulation 1.409A-3(i)(5)(v) or 1.409A-3(i)(5)(vii). 
 (d) “CIC Qualifying Termination” means a Separation
(A) within twelve (12) months following a Change in Control or (B) within three (3) months preceding a Change in Control (but as to part (B), only if the Separation occurs after a Potential Change in Control) resulting, in either
case (A) or (B), from (i) the Company or its subsidiary, as applicable, terminating the Employee’s employment for any reason other than Cause or (ii) the Employee voluntarily resigning his or her employment for Good Reason. A
termination or resignation due to the Employee’s death or disability shall not constitute a CIC Qualifying Termination. A “Potential Change in Control” means the date of execution of a legally binding and definitive agreement
for a corporate transaction which, if consummated, would constitute the applicable Change in Control (which for the avoidance of doubt, would include a merger agreement, but not a term sheet for a merger agreement). In the case of a termination
following a Potential Change in Control and before a Change in Control, solely for purposes of benefits under this Agreement, the date of Separation will be deemed the date the Change in Control is consummated. 

(e) “Good Reason” means, without the Employee’s consent, (i) a material reduction in the Employee’s level of
responsibility and/or scope of authority, (ii) a reduction by more than 10% in Employee’s base salary (other than a reduction generally applicable to Employee officers of the Company or its subsidiary, as applicable, and in generally the
same proportion as for the Employee), or (iii) relocation of the Employee’s principal workplace by more than thirty-five (35) miles from Employee’s then current place of employment. For the purpose of clause (i), a change in
responsibility shall not be deemed to occur (A) solely because Employee is part of a larger organization or (B) solely because of a change in title. For the Employee to receive the benefits under this Agreement

  
 4 

 
as a result of a voluntary resignation under this subsection (e), all of the following requirements must be satisfied: (1) the Employee must provide notice to the Company or its subsidiary,
as applicable, of his or her intent to assert Good Reason within sixty (60) days of the initial existence of one or more of the conditions set forth in subclauses (i) through (iii); (2) the Company or its subsidiary, as applicable,
will have thirty (30) days (the “Company Cure Period”) from the date of such notice to remedy the condition and, if it does so, the Employee may withdraw his or her resignation or may resign with no benefits; and (3) any
termination of employment under this provision must occur within ten (10) days of the earlier of expiration of the Company Cure Period or written notice from the Company or its subsidiary, as applicable, that it will not undertake to cure the
condition set forth in subclauses (i) through (iii). Should the Company or its subsidiary, as applicable, remedy the condition as set forth above and then one or more of the conditions arises again within twelve months following the occurrence
of a Change in Control, the Employee may assert Good Reason again subject to all of the conditions set forth herein. 
 (f) “Release
Conditions” mean the following conditions: (i) Company has received the Employee’s executed Release and (ii) any rescission period applicable to the Employee’s executed Release has expired. 

(g) “Qualifying Termination” means a Separation that is not a CIC Qualifying Termination, but which results from (i) the
Company or its subsidiary, as applicable, terminating the Employee’s employment for any reason other than Cause or (ii) the Employee voluntarily resigning his or her employment for Good Reason. A termination or resignation due to the
Employee’s death or disability shall not constitute a Qualifying Termination. 
 (h) “Separation” means a
“separation from service,” as defined in the regulations under Section 409A of the Code. 
 8. Successors. 

(a) Company’s Successors. The Company shall require any successor (whether direct or indirect and whether by purchase, lease,
merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets, by an agreement in substance and form satisfactory to the Employee, to assume this Agreement and to agree expressly to perform
this Agreement in the same manner and to the same extent as the Company would be required to perform it in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any successor to the
Company’s business and/or assets or which becomes bound by this Agreement by operation of law. 
 (b) Employee’s
Successors. This Agreement and all rights of the Employee hereunder shall inure to the benefit of, and be enforceable by, the Employee’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees
and legatees. 
 9. Golden Parachute Taxes. 

(a) Best After-Tax Result. In the event that any payment or benefit received or to be received by Employee pursuant to this Agreement
or otherwise (“Payments”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by
Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (“Excise Tax”), then, subject to the provisions of Section 10, such Payments shall be either
(A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent which would result in no portion of such Payments being subject to the Excise Tax (“Reduced
Amount”), whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such
taxes), results in the receipt by Employee, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax.
Unless the Company and Employee 

  
 5 

 
otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to Employee
(“Independent Tax Counsel’), whose determination shall be conclusive and binding upon Employee and the Company for all purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make
reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume
that Employee pays all taxes at the highest marginal rate. The Company and Employee shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this
Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that Section 9(a)(ii)(B) above applies, then based on the information
provided to Employee and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will
otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the “IRS”) determines that any Payment is subject to the Excise Tax, then Section 9(b) hereof shall apply, and the
enforcement of Section 9(b) shall be the exclusive remedy to the Company. 
 (b) Adjustments. If, notwithstanding any reduction
described in Section 9(a) hereof (or in the absence of any such reduction), the IRS determines that Employee is liable for the Excise Tax as a result of the receipt of one or more Payments, then Employee shall be obligated to surrender or pay
back to the Company or its subsidiary, as applicable, within one-hundred twenty (120) days after a final IRS determination, an amount of such payments or benefits equal to the “Repayment Amount.” The Repayment Amount with
respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company or its subsidiary, as applicable, so that Employee’s net proceeds with respect to such Payments (after taking into
account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero (0) if a Repayment Amount of more than zero (0) would not
eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received by Employee from the Payments. If the Excise Tax is not eliminated pursuant to this Section 9(b), Employee
shall pay the Excise Tax. 
 10. Miscellaneous Provisions. 

(a) Section 409A. To the extent (i) any payments to which Employee becomes entitled under this Agreement, or any agreement or
plan referenced herein, in connection with Employee’s termination of employment with the Company or its subsidiary, as applicable, constitute deferred compensation subject to Section 409A of the Code and (ii) Employee is deemed at the
time of such termination of employment to be a “specified” employee under Section 409A of the Code, then such payment or payments shall not be made or commence until the earlier of (i) the expiration of the six (6)-month period
measured from the Employee’s Separation; or (ii) the date of Employee’s death following such Separation; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to
Employee, including (without limitation) the additional twenty percent (20%) tax for which Employee would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable
deferral period, any payments which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to Employee or Employee’s beneficiary in one lump sum (without
interest). Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit under this Agreement (or otherwise referenced herein) is determined to be subject to (and not exempt from)
Section 409A of the Code, the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect the expenses eligible for reimbursement or in kind benefits to be provided in
any other calendar year, in no event shall any expenses be reimbursed after the last day of the calendar year following the calendar year in which Employee incurred such expenses, and in no event shall any right to reimbursement or the provision of
any in-kind benefit be subject to liquidation or exchange for another benefit. To the extent that any provision of this Agreement is ambiguous as to its exemption or compliance with 

  
 6 

 
Section 409A, the provision will be read in such a manner so that all payments hereunder are exempt from Section 409A to the maximum permissible extent, and for any payments where such
construction is not tenable, that those payments comply with Section 409A to the maximum permissible extent. To the extent any payment under this Agreement may be classified as a “short-term deferral” within the meaning of
Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this Agreement (or referenced in this
Agreement) are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the regulations under Section 409A. 

(b) Other Arrangements. This Agreement supersedes any and all cash severance arrangements and vesting acceleration arrangements on
change in control under any prior option agreement, restricted stock unit agreement, severance and salary continuation arrangements, programs and plans which were previously offered by the Company or its subsidiary, as applicable, to the Employee,
including change in control severance arrangements and vesting acceleration arrangements pursuant to an employment agreement or offer letter, and Employee hereby waives Employee’s rights to such other benefits. In no event shall any individual
receive cash severance benefits under both this Agreement and any other severance pay or salary continuation program, plan or other arrangement with the Company or its subsidiaries. For the avoidance of doubt, in no event shall Employee receive
payment under both Section 2 and Section 3 with respect to Employee’s Separation. 
 (c) Dispute Resolution. To ensure
rapid and economical resolution of any and all disputes that might arise in connection with this Agreement, Employee and the Company agree that any and all disputes, claims, and causes of action, in law or equity, arising from or relating to this
Agreement or its enforcement, performance, breach, or interpretation, will be resolved solely and exclusively by final, binding, and confidential arbitration, by a single arbitrator, in San Francisco County, and conducted by Judicial
Arbitration & Mediation Services, Inc. (“JAMS”) under its then-existing employment rules and procedures. Nothing in this section, however, is intended to prevent either party from obtaining injunctive relief in court to
prevent irreparable harm pending the conclusion of any such arbitration. Each party to an arbitration or litigation hereunder shall be responsible for the payment of its own attorneys’ fees. 

(d) Notice. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been
duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid or deposited with Federal Express Corporation, with shipping charges prepaid. In the case of the Employee, mailed
notices shall be addressed to him or her at the home address which he or she most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be
directed to the attention of its Secretary. 
 (e) Waiver. No provision of this Agreement shall be modified, waived or discharged
unless the modification, waiver or discharge is agreed to in writing and signed by the Employee and by an authorized officer of the Company (other than the Employee). No waiver by either party of any breach of, or of compliance with, any condition
or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time. 

(f) Withholding Taxes. All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required
to be withheld by law. 
 (g) Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall
not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. 
 (h) No Retention
Rights. Nothing in this Agreement shall confer upon the Employee any right to continue in service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company or any subsidiary of the Company
or of the Employee, which rights are hereby expressly reserved by each, to terminate his or her service at any time and for any reason, with or without Cause. 

  
 7 

 (i) Choice of Law. The validity, interpretation, construction and performance of this
Agreement shall be governed by the laws of the State of Texas (other than its choice-of-law provisions). 

  
 8 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by its duly authorized officer, as of the day and year first above written. 
  

			
	AEGLEA BIOTHERAPEUTICS, INC.
		 	  
 /s/ David G. Lowe

		 	 By:        David G. Lowe, Ph.D.

Title:     Chief Executive Officer

  

			
		 	/s/ Henry L. Hebel
		 	Henry L. Hebel

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]